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Poor immunological responders (PIR) are HIV-infected patients with virologic suppression
upon antiretroviral therapy (ART) but persistently low CD4+ T cell counts. Early
identification of PIR is important given their higher morbimortality compared to adequate
immune responders (AIR). In this study, 33 patients severely lymphopenic at ART onset,
were followed for at least 36 months, and classified as PIR or AIR using cluster analysis
grounded on their CD4+ T cell count trajectories. Based on a variety of immunological
parameters, we built predictive models of PIR/AIR outcome using logistic regression. All
PIR had CD4+ T cell counts consistently below 500 cells/µL, while all AIR reached this
threshold. AIR showed a higher percentage of recent thymic emigrants among CD4+ T
cells; higher numbers of sj-TRECs and greater sj/β TREC ratios; and significant increases
in thymic volume from baseline to 12 months of ART. We identified mathematical
models that correctly predicted PIR/AIR outcome after 36 months of therapy in 77–87%
of the cases, based on observations made until 2–6 months after ART onset. This
study highlights the importance of thymic activity in the immune recovery of severely
lymphopenic patients, and may help to select the patients that will benefit from closer
follow-up or novel therapeutic approaches.
Keywords: poor immunological responders, predictive modeling, immune recovery, CD4+ T cells, thymic function,
immune activation, antiretroviral therapy, HIV infection
INTRODUCTION
The majority of patients infected by the human immunodeficiency virus (HIV) show immune
recovery upon antiretroviral therapy (ART). This recovery usually occurs with a rapid increase in
CD4+ T cell numbers during the first few months, followed by a slower increase toward a plateau
(1–3). An adequate immune recovery is defined as the attainment of CD4+ T cell counts within the
range observed in healthy adult individuals (i.e., 500–1,500 cells/µL). However, CD4+ T cell counts
remain persistently low in 9–45% of patients, depending on the criteria used, despite complete viral
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suppression (i.e., undetectable plasma HIV RNA) (4–6). There
is no consensual case-definition for these patients, and dozens
of different terms are used in the literature to refer to them,
such as “poor immunological responders”, “immunological non-
responders”, and “discordant immune responders” (5). In this
study, we use the terms poor and adequate immunological
responders (PIR and AIR), because these seem to be the terms
that best reflect patients’ immunologic response to therapy.
Distinct immune recovery trajectories throughout ART result
from differences in CD4+ T cell production by the thymus,
peripheral proliferation, virus- or immune-mediated cell death
and/or ability to obtain survival stimuli. Differences in recovery
may also derive from variations in the extent of CD4+ T cell
migration from lymphoid tissues to peripheral blood or to the
gastrointestinal tract soon after ART initiation (1, 7, 8).
Production of new T cells by the thymus appears to be a
major driver of immune recovery during ART, being particularly
relevant for patients who start therapy with <200 CD4+ T
cells/µL, in whom poor immune responses are more frequent
(9–16). Many other factors have been associated with poor
immune recovery, such as older age, lower nadir CD4+ T cell
counts, residual viral replication, increased T cell death, immune
hyperactivation, altered ratio of regulatory T cells (Treg) to Th17
cells, tissue fibrosis [reviewed in (17, 18)] and specific metabolic
profiles (19).
PIR have higher morbidity and mortality rates than AIR (20–
22). Therefore, there is an urgent need for tools to identify PIR
early and improve their prognoses. This study discriminated
PIR and AIR among patients with acquired immunodeficiency
syndrome (AIDS) and <200 CD4+ T cells/µL at ART onset, not
using any of the many clinical criteria reported in the literature,
but instead using clustering analysis of longitudinal data. For this
analysis, we simply specified that patients should be divided into
2 clusters on the basis of their CD4+ T cell count trajectories.
A posteriori analysis of the trajectories revealed that one cluster
included patients whose trajectories reached higher CD4+ T cell
counts, with all patients in that cluster presenting > 500 CD4+
T cells/µL at least at one time point over the first 36 months
of therapy (AIR), contrary to patients of the other cluster (PIR).
In addition, immunological parameters were compared between
PIR and AIR and early alterations were identified as predictors of
PIR status after 36 months of therapy.
MATERIALS AND METHODS
Study Participants
Patients infected by HIV, with <200 CD4+ T cells/µL at ART
initiation and with ≥36 months of follow-up were selected
(n=33) from a prospective cohort of patients (n=100 individuals;
Figure S1) on medical care at the Centro Hospitalar do Porto,
Portugal. The enrolment period ran between April 2010 and
Abbreviations: ACC, accuracy; AIC, Akaike information criterion; AIR, adequate
immunological responders; ART, antiretroviral therapy; AUC, area under the
curve; CT, computed tomography; IQR, interquartile range; LRT, likelihood
ratio test; PBMCs, peripheral blood mononuclear cells; PIR, poor immunological
responders; RTE, recent thymic emigrants; TRECs, T cell receptor excision circles;
Treg, regulatory T cells.
October 2012. All patients were provided an explanation of
the study and signed an informed consent (local Ethical
Committee approval—reference 168/CES); were older than 18
years, chronically infected with HIV-1, ART-naïve at enrolment
and with clinical criteria to initiate ART. ART schemes chosen
for each individual took into consideration national and
international guidelines. All patients were therapy compliant
throughout the follow-up; after a median time of 6 months of
ART, all patients presented sustained plasma viral loads below
50 copies/mL, except for 4 individuals who had viral blips
(Figure S2). Clinical information and peripheral blood samples
were retrieved at baseline (just before ART initiation) and at
2, 6, 12, 16, 20, 24, 28, 32, 36, 42, 48, 54, and 60 months of
ART (median time deviations to each time point was ≤8 days).
Individuals were followed for at least 36 months, with median
follow-up time of 60 months. CD4+ T cell counts and plasma
viral load quantification were assessed at all available time points
by a certified laboratory.
Imaging
Sixteen of the 33 patients underwent chest computed
tomography (CT) scans at baseline and at 12 months of
ART (Figure S1). CT scans were performed without contrast in
a Siemens Somatom emotion apparatus (16 sections). Thymic
volume was considered as the mean of measurements, blindly
performed by two independent operators, in cm3. Thymic
index, assessed by one of the operators, was determined by
scoring the presence of thymic tissue as opposed to adipose
tissue: (0) thymus entirely replaced by fat; (1) minimal, barely
recognizable, soft tissue; (2) minimal, but more obvious, soft
tissue; (3) moderate soft tissue; (4) moderate soft tissue of greater
extent, almost mass like; (5) mass-like appearance that raises
concern for a thymoma (23). Both operators were blinded to any
demographic or clinical data besides the HIV serostatus.
Blood Processing and Flow Cytometry
(FACS) Analysis
For each participant and at each time point, venous blood
was collected to K2EDTA collecting tubes and processed on
the same day. A blood aliquot for FACS analysis was taken
and, from the remaining blood, PBMCs were isolated by
gradient centrifugation using Histopaque 1077 (Sigma-Aldrich,
United Kingdom). After PBMCs’ enumeration, 2× 106 cells were
used for FACS staining and 1 × 106 cells aliquots were stored at
−80 ◦C for TRECs quantification.
For FACS, three antibody panels were design for evaluation
of T cell activation (Panel 1, performed in 100 µL of whole
blood), recent thymic emigrants (RTE; Panel 2, performed in
200 µL of whole blood) and Treg (Panel 3, performed in 2 ×
106 PBMCs), as previously described (24). A mixture of anti-
CD45RA-FITC (HI100), anti-CD69-PE (FN50), anti-CD45RO-
PerCP/Cy5.5 (UCHL1), anti-HLA-DR-PeCy7 (L243), anti-CD8-
APC (RPA-T8), anti-CD4-APC/Cy7 (RPA-T4), and anti-CD3-
Pacific Blue (OKT3) was used for Panel 1; a mixture of anti-
CD45RA-FITC (HI100), anti-CD3-PE (OKT3), anti-CD45RO-
PerCP/Cy5.5 (UCHL1); anti-CD31-PeCy7 (WM59), anti-CCR7-
Alexa Fluor 647 (G043H7), anti-CD4-APC/Cy7 (RPA-T4), and
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anti-CD8-Brilliant Violet 421 (RPA-T8) was used for Panel
2; and a mixture of anti-Ki67-FITC (MOPC-21), anti-FoxP3-
PE (PCH101), anti-CD127-PerCP/Cy5.5 (AO19D5), anti-CD31-
PeCy7 (WM59), anti-CD25-APC (BC96), anti-CD4-APC/Cy7
(RPA-T4), anti-CD45RA-Pacific Blue (HI100), and anti-CD3-
V500 (UCHT1) was used for Panel 3. All antibodies were
from BioLegend, except for anti-CD3-V500 (BD Horizon),
anti-FoxP3-PE (eBiosciences) and anti-Ki67 (BD Pharmigen).
Samples were acquired using a BD LSRII flow cytometer using
FACS DIVA software (Becton and Dickinson, NJ, USA); data
were analyzed using FlowJo Software (Tree Star, OR, USA).
Gating strategies are depicted in Figure S3.
Quantification of T Cell Receptor Excision
Circles (TRECs)
TRECs were quantified at baseline, 6, 12, 24, and 36 months of
ART in 14 of the 33 patients (Figure S1). Quantification of sj-
TRECs and DJβ1-TRECs was performed by nested polymerase
chain reaction (PCR), using primers and standard curve’s
plasmids as previously described (25, 26). Briefly, 1× 106 PBMCs
were lysed in Tween-20 (0.05%), nonidet P-40 (NP-40; 0.05 %),
and Proteinase K (100µg/mL) for 30min at 56 ◦C followed by
15min at 98 ◦C. Multiplex PCR amplification was performed
using the specific “out” primers for sj-TREC or for each of the
6 DJβ1-TREC, together with the CD3 chain (10min at 95 ◦C
followed by 22 cycles of 30 s at 95 ◦C, 30 s at 60 ◦C and 3min at
72 ◦C) using the 5′/3′ out primer pairs. Following the first round
of amplification, each PCR product was 100-fold diluted; from
the same diluted PCR product, TREC and CD3 were quantified
in independent qPCR runs using a LightCycler R© system (Roche
Diagnostics, Basel, Switzerland). Using the specific “in” primers,
qPCR amplification was as follows: 15min at 95 ◦C, followed
by 45 cycles of 1 s at 95 ◦C, 15 s at 55 ◦C and 10 s at 72 ◦C;
fluorescence was measured at the end of each cycle. Results were
expressed both as number of TRECs/105 cells and number of
TRECs/mL.
Statistical Analysis
Statistical analysis was performed in the computing environment
R (v3.4.2) using RStudio (v1.1.383). Overall, a p-value <0.05 (α)
was considered statistically significant; for multiple comparisons,
Bonferroni corrections were applied and differences or effects
that remained significant (< α/number of comparisons) are
indicated in the Figures with a ∗.
The R package traj (v1.2) was used to identify two clusters
of patients based on their CD4+ T cell counts trajectories
from baseline to 36 months of ART. The package implements
the 3-step procedure proposed by Leffondré et al. (27) to
identify clusters of longitudinal trajectories: first, 24 summary
measures (Table S1) that describe features of the trajectories
were calculated (28); second, a principal component analysis
was performed on these 24 measures to select measures that
best describe the main features of the trajectories, based on
eigenvalues (>1); finally, trajectories were classified into clusters
based on the previously selected factors.
We used the nlme package (v3.1.137) in R to fit nonlinear
mixed effects models to the CD4+ T cell count and the CD4/CD8
ratio data, based on the exponential model described by Li
et al. (9):
X(t) = A+ B [1− exp(−t / τ )]
where X(t) represents CD4+ T cell count or CD4/CD8 ratio
at one given time point t; A represents the theoretical CD4+
T cell count or CD4/CD8 ratio at baseline; B represents the
theoretical maximum increase that could be reached; t refers
to time (in months) since ART initiation; and τ is a constant
representing the timescale over which X(t) reaches its maximum
value. The arguments used in the CD4+ T cell count models
were: fixed = list (A ∼ 1, B ∼ group, τ ∼ group) and
random= A+ B∼ 1 | Patient_ID, where Patient_ID correspond
to the identification of each patient. The arguments used in the
CD4/CD8 ratio models were: fixed = list (A ∼ 1, B ∼ group, τ
∼1) and random= A+ B+ τ ∼ 1 | Patient_ID.
Normality of data distributions was assessed by the Shapiro-
Wilk test. Correlations were assessed using the Pearson or
Spearman rank tests, depending on the underlying distribution.
For quantitative data, depending on the underlying distributions,
comparisons between two independent groups were performed
using an independent t-test or Wilcoxon/Mann-Whitney U-
test, unless otherwise stated. Cohen’s d or r, respectively, was
calculated as a measure of effect size. Within-group comparisons
between two time points were performedwith the paired-samples
t-test (for approximately normally-distributed data); in this case,
Cohen’s d was calculated based on the standard deviation of
the differences. For qualitative data, comparison was performed
using Fisher exact test; effects sizes were described with the odds
ratio (dichotomous variables) or Cramér’s V (nominal variables
with>2 categories) (29).
Effect sizes were assessed as follows:
- Cohen’s d: small if<0.3; medium if [0.3,0.8]; or large if ≥0.8;
- r: small if<0.3; medium if [0.3, 0.5]; or large if ≥0.5;
- Cramér’s V: small if<0.3; medium if [0.3,0.7]; or large if> 0.7;
- Correlation coefficient (r or ρ): negligible if <0.3; low if [0.3;
0.5]; moderate if [0.5; 0.7]; high if [0.7; 0.9]; or very high if [0.9;
1.0].
All statistical tests performed were two-tailed. Extreme outliers
were defined as lower than P25 – 3 × Interquartile range (IQR)
or higher than P75 + 3 × IQR. All tests were performed with
and without extreme outliers to verify their effect on the p-value
and all results pointed to the same direction (with significant or
non-significant p-values) after exclusion of the extreme outliers.
All the results reported included the extreme outliers.
Logistic regression analysis was conducted using the
glm() function in R (v3.4.3) to identify associations between
independent variables, assessed between baseline and 6 months
on ART (inclusively), and the dependent variable “Being AIR
or PIR” (Y = 1 for “AIR”; Y = 0 for “PIR”). Selection of
variables for the multivariate analysis included a univariable
logistic regression analysis for each candidate to detect potential
predictors (p-value < 0.20). A backward stepwise selection
procedure was performed, analyzing the significance of the
coefficient for each variable at each step, until no further
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improvement was possible. The adequacy of the final model
was assessed by means of a likelihood ratio test (LRT, reduced
model vs. full model). The Akaike information criterion (AIC)
was used to compare models with the same observations.
The Hosmer-Lemeshow test for goodness-of-fit was applied
to the final model and diagnostic plots were carried out as
well, including ROC curve. The area under the curve (AUC)
statistic was also calculated as a measure of goodness-of-fit,
considering: [0.5; 0.7], poor; [0.7; 0.8], fair; [0.8; 0.9], good; and
>0.9, excellent. For each model, all patients were classified as
“probably PIR” (probability of being PIR ≥0.5) or “probably
AIR” (probability of being PIR <0.5). Sensitivity and specificity
were calculated as the percentage of “probably PIR” among PIR
and the percentage of “probably AIR” among AIR, respectively.
Accuracy (ACC) was calculated as the percentage of patients
PIR or AIR that were respectively classified as “probably PIR” or
“probably AIR” among all patients. Relevant R code is available in
Supplementary Material.
RESULTS
Analysis of CD4+ T Cell Counts
Trajectories Identified Two Clusters of
Patients With Distinct Kinetics of Immune
Recovery
Demographic and clinical characteristics of the patients are
presented in Table 1.
The CD4+ T cell count trajectories of the 33 patients were
automatically analyzed using R traj package, and two clusters
were formed (Figure 1A;Table S2). From the summarymeasures
considered for each trajectory (Table S1), the main descriptors of
the CD4+ T cell count trajectories were range and change relative
to the mean over time.
All patients in cluster 1 (n = 14) had at least one CD4+ T cell
count above 500 cells/µL during the first 36 months of ART, and
were classified as AIR. Patients in cluster 2 (n= 19) had all CD4+
T cell counts bellow 500 cells/µL, during the same time period,
and were classified as PIR (Figures 1A, S4A,B).
At baseline, PIR tended to be older, with lower CD4/CD8
ratios, and had significantly lower plasma viral loads; there
were no significant differences in baseline CD4+ cell counts
between PIR and AIR (Table 1). After 12 months of ART, AIR
exhibited significantly higher CD4+ T cell counts than PIR. This
difference became progressivelymore evident throughout follow-
up (Figure 1A). AIR consistently presented higher median rates
of increase of CD4+ T cell counts during the first 12 months of
ART (Table 2). The CD4/CD8 ratio tended to be lower in PIR
than AIR at all time points (Figures 1B, S4C,D).
The adjusted kinetics for CD4+ T cell counts and CD4/CD8
ratio in PIR, obtained using nonlinear mixed effects models,
were:
CD4 count (t) = 130.1 + 284.5 [1 − exp(−t/31.9) ]
CD4/CD8 (t) = 0.163 + 0.475 [1− exp(−t/27.620)]
and in AIR:
CD4 count (t) = 130.1 + 499.0 [1 − exp(−t/17.6) ]
CD4/CD8 (t) = 0.163 + 0.644 [1− exp(−t/27.620)]
These kinetics indicate that on long-term ART, mean CD4+ T
cell counts among PIR asymptoted to 414.6 cells/µL and the
CD4/CD8 ratio to 0.638; these quantities stabilized at 629.1 and
0.807, respectively, in AIR (Figures 1C,D).
CD4+ T Cell Proliferation and Activation
Status Did Not Differ Between PIR and AIR
We did not detect differences in CD4+ T cell division rates, as
assessed by Ki67 expression (Figures 2A,B, S5A,B), nor in their
activation status (CD69+ cells; Figure 2C). Absolute numbers of
CD69+CD4+ T cells were higher in AIR at 12 months of ART,
reflecting their greater CD4+ T cell counts (Figures 2D, S5C,D).
Diverse immune recoveries have been associated with
differences in CD4+ T cell proliferation and activation (30–
32). To assess whether the apparent discrepancy between these
associations and our results could be related to CD4+ T cell
counts at baseline, we analyzed a group of HIV-infected patients
who started ART with CD4+ T cell counts in the range 200–350
cells/µL, who achieved full virologic suppression and adequate
immune recovery (referred to as HIV-infectedBL[200−350]). These
individuals presented lower percentages of Ki67+ cells and of
CD69+ cells among CD4+ T cells than PIR or AIR at baseline
(Figure S7).
No substantial differences were observed between AIR
and PIR in either percentage or absolute numbers of Treg
(CD25highCD127−Foxp3+ CD4+ T cells; Figures 2E,F, S5E,F).
The naïve/memory CD4+ T cell ratio (i.e.,
CD45RA+CD45RO−/CD45RA−CD45RO+) was tendentially
higher in AIR than in PIR at baseline and 6 months, and
significantly higher at 12, 24, and 36months of ART (Figures 2G,
S4E,F), which is consistent with naïve cells contributing more to
CD4+ T cell recovery in AIR than in PIR.
AIR Presented Higher Thymic Function
Since Baseline, Independently of Age
Differences
Thymic function was characterized using three distinct metrics:
(1) assessment of thymic index (defined in the imaging
subsection of the Methods) and volume, at baseline and
12 months of ART; (2) quantification of peripheral blood
TRECs at baseline, 6, 12, 24, and 36 months of ART);
and (3) quantification of recent thymic emigrants (RTE;
CD4+CD3+CD45RA+CD31+) in blood, at baseline, 6, 12, 24,
and 36 months of ART. AIR and PIR presented similar thymic
volumes at baseline and at 12 months of ART. However, AIR
exhibited significant increases in thymic volume during that
period, while PIR did not (variations of 6.47 ± 4.59 cm3 vs.
1.43 ± 4.89 cm3, respectively; Figure 3A). PIR tended to present
lower thymic index, both at baseline and 12 months of ART
(Figure 3B). A thymic score was calculated as the product of
thymic volume and index means, over the first year of ART. AIR
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TABLE 1 | Demographic and clinical characteristics of HIV-infected patients included in the study.
Total
n = 33
AIR
n = 14
PIR
n = 19
AIR vs. PIR
Gender, male:female, n (%) 23:10
(70%: 30%)
9:5
(64%: 36%)
14:5
(74%: 26%)
p = 0.707a, OR = 0.64
Age at baseline, in years
Mean ± SD
Range [Min; Max]
42.2 ± 10.4
[23; 67]
38.1 ± 8.6
[23,51]
45.3 ± 10.8
[28; 67]
t(31) = −2.032, p = 0.051
b,
Cohen’s d = 0.72
HIV viral load at baseline,
in log10 copies per mL,
Median [Min; Max]
5.57 [4.78; 6.98] 5.96 [5.25; 6.98] 5.41 [4.78; 6.84] U = 203, p = 0.011c, r = −0.44
CD4+ T cell count at baseline,
in cells/µL, Median [Min; Max] 67 [8; 193] 93 [12; 193] 61 [8; 182] U = 167, p = 0.229c, r = −0.21
CD4/CD8 ratio at baseline,
Mean ± SD
Range [Min; Max]
0.122 ± 0.095
[0.010; 0.373]
0.160 ± 0.113
[0.017; 0.373]
0.095 ± 0.070
[0.010; 0.272]
t(31) = 2.032, p = 0.051
b,
Cohen’s d = 0.72
Clinical categories*, n (%)
A (Asymptomatic or acute HIV infection) 3 (9%) 1 (7%) 2 (11%)
B (not A or C) 14 (42%) 4 (29%) 10 (53%) p = 0.262a, Cramér’s V = 0.27
C (AIDS-defining conditions) 16 (48%) 9 (64%) 7 (37%)
Co-infections at baseline, n (%)
HCV 9 (27%) 2 (14%) 7 (37%) p = 0.241a, OR = 3.50
HBV 1 (3%) 1 (7%) 0 (0%) p = 0.424a, OR = 0.00
HIV subtype, n (%)
B 13 (39%) 5 (36%) 8 (42%)
G 11 (33%) 4 (29%) 7 (37%)
C 4 (12%) 2 (14%) 2 (11%) p = 0.633a, Cramér’s V = 0.40
Other 4 (12%) 3 (21%) 1 (5%)
Unknown 1 (3%) 0 (0%) 1 (5%)
HIV transmission mode, n (%)
Intravenous drug user 6 (18%) 1 (7%) 5 (26%)
Men who have sex with men 9 (27%) 5 (36%) 4 (21%)
Heterosexual 15 (45%) 6 (43%) 9 (47%) p = 0.567a, Cramér’s V = 0.27
Other 2 (6%) 1 (7%) 1 (5%)
Unknown 1 (3%) 1 (7%) 0 (0%)
Time from diagnosis to baseline,
in months, Median [Min; Max] 5 [0; 128] 23 [1; 85] 3 [0; 128] U = 179, p = 0.096c, r = −0.29
ART regimen components, n (%)
2 NRTIs: TDF+FTC 29 (88%) 14 (100%) 15 (79%)
ABC+3TC 3 (9%) 0 (0%) 3 (16%) p = 0.244a, Cramér’s V = 0.32
AZT+3TC 1 (3%) 0 (0%) 1 (5%)
3rd Drug: EFV 25 (76%) 10 (71%) 15 (79%)
DRV/r 6 (18%) 4 (29%) 2 (11%) p = 0.473a, Cramér’s V = 0.30
LPV/r 1 (3%) 0 (0%) 1 (5%)
NVP 1 (3%) 0 (0%) 1 (5%)
HIV drug resistance, n (%)
Yes 11 (33%) 3 (21%) 8 (42%)
No 21 (64%) 11 (79%) 10 (53%) p =0.266a, OR = 0.34
Unknown 1 (3%) 0 (0%) 1 (5%)
*Based on Centers for Disease Control and Prevention (CDC) Classification System.
aFisher’s exact test. b Independent t-test. cWilcoxon/Mann-Whitney U test.
Values in bold indicate statistically significant difference (p < 0.05) between AIR and PIR. ABC, abacavir; DRV/r, ritonavir boosted darunavir; EFV, efavirenz; FTC, emtricitabine; HBV,
Hepatitis B virus; HCV, Hepatitis C virus; LPV/r, ritonavir boosted lopinavir; NRTI, nucleoside or nucleotide analogue reverse transcriptase inhibitors; NVP, nevirapine; OR: odds ratio;
TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.
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FIGURE 1 | Despite having similar CD4+ T cell counts at ART onset, AIR reached higher CD4+ T cell counts as soon as 2 months after ART initiation. (A) CD4+ T
cell counts and (B) CD4/CD8 ratio were compared throughout ART between AIR and PIR. A Wilcoxon-Mann-Whitney U-test was performed to compare the two
groups of patients at each time point, and the correspondent r is presented as a measure of effect size. *Significant after Bonferroni correction (α/14 = 0.004).
(C,D) Nonlinear mixed effects models for CD4+ T cell count and CD4/CD8 ratio evolutions, respectively. White squares represent AIR mean of CD4+ T cell count
(C), or CD4/CD8 ratio (D) at each time point; black squares represent PIR mean of CD4+ T cell count (C), or CD4/CD8 ratio (D) at each time point. Black dotted lines
in (A) and (C) correspond to Y = 500. Gray dashed lines correspond to the asymptotes: Y = 629.1 and Y = 414.6 (C); Y = 0.807 and Y = 0.638 (D), respectively.
TABLE 2 | CD4+ T cell count slopes during ART.
CD4+ T cell count slope, in cells/µL/montha, Median [P25; P75]
Time interval during ART,
in months
Total
n = 33
AIR
n = 14
PIR
n = 19
AIR vs. PIR
[0; 2] 57 [29; 102] 87 [50; 107] 48 [21; 69] U = 191, p = 0.036b, r = 0.36
[2,12] 7 [2,13] 14 [10,17] 3 [1,7] U = 228, p < 0.001b, r = 0.60
[12,24] 5 [2,10] 6 [-1; 13] 5 [3,10] U = 135, p = 0.956b, r = 0.01
[24,36] 3 [1,9] 12 [2,17] 2 [1,4] U = 198, p = 0.019b, r = 0.41
[36,48] 3 [0; 8] 2 [−4; 10] 3 [1,7] U = 68, p = 0.544b, r = 0.12
[48,60] 5 [1,9] 7 [1,11] 5 [1,7] U = 23, p = 0.830b, r = 0.06
aCD4 count slopes from time point ti to tf were calculated for each individual by the least squares estimation method, including all the available CD4 counts between ti and tf .
bWilcoxon/Mann–Whitney U-test.
Bold values indicate statistically significant difference (p < 0.05) between AIR and PIR.
had a tendency to present higher thymic scores (Figure 3C). We
also compared thymic volume, index and score between HIV-
infectedBL[200−350] and AIR and PIR, respectively. Interestingly,
AIR, but not PIR, presented higher thymic volume at 12 months
of ART and higher thymic score than HIV-infectedBL[200−350]
(Figure S8).
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FIGURE 2 | Throughout ART, PIR and AIR presented no major differences in CD4+ T cell activation status, proliferation, Treg numbers, nor naïve/memory CD4+ T cell
ratio. (A) The percentage among CD4+ T cells and (B) absolute number of Ki67+ cells, (C,D) CD69+ cells, (E,F) Treg (CD25highCD127−FoxP3+CD4+ T cells) and
(G) naïve/memory CD4+ T cell ratio were compared throughout therapy in AIR and PIR. A Wilcoxon-Mann-Whitney U-test was performed to compare the two groups
of patients at each time point, and the corresponding r is presented as a measure of effect size. *Significant after Bonferroni correction (α/5 = 0.010).
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FIGURE 3 | AIR presented thymic volume increase during the first 12 months of ART. (A) Thymic volumes and (B) thymic indices were compared between AIR and
PIR at baseline and at 12 months of ART. Thymic indices ranged from 1 to 3. (C) Thymic scores were calculated as the product of thymic volume and index means,
over the first year of ART. Thymic volumes and scores (A,C) were compared using independent t-tests and the correspondent effect size estimates were calculated
using for Cohen’s d. Thymic indices (B) were compared using Fisher’s exact test and effect size estimates were calculated using Cramér’s V.
Furthermore, AIR tended to present higher frequencies
of sj-TRECs (numbers per 105 PBMCs) at 24 months of
ART (Figure 4A), and significantly higher numbers of sj-
TRECs/mL of blood and sj/β TREC ratios at the same
time point (Figures 4B,C, S6A,B; Table S3). Absolute
numbers and percentage of RTE among CD4+ T cells
were higher in AIR than in PIR throughout the follow-
up period, except at baseline and, for the percentage
of RTE, at 6 months of ART (Figures 5A,B, S6C–F;
Table S4).
We found no correlation between patients’ age and any of
the surrogates of thymic function (Table S5). We also found no
correlations between thymic volume (at baseline or at 12 months
of ART) and RTE absolute number or percentage among CD4+
T cells at any other time point.
Age, HIV Viral Load, and RTE Percentages
at Early Stages of ART Had Predictive
Value for Immune Recovery, in Addition to
CD4+ T Cell Counts
We performed univariate logistic regressions with all variables
to identify predictors of PIR or AIR status. The variables that
performed the best (considering the lowest LRT p-values) were:
CD4+ T cell count at 6 months of ART (LRT p-value = 0.003,
AUC = 0.774, ACC = 69.7%), CD4+ T cell count at 2 months
of ART (LRT p-value = 0.007, AUC = 0.750, ACC = 74.2%)
or CD4+ T cell count slope from baseline to 6 months of
ART (LRT p-value = 0.010, AUC = 0.756, ACC = 60.6%).
Performing combinations of eight elements from the set of
variables identified in the univariate analysis with p < 0.200,
and applying a stepwise selection, four logistic models, with
three independent variables and an area under the curve (AUC)
>0.80, were obtained (Models 1–4). Each of the models were
represented by the following equation:
Probability
of being
PIR
=
1
1+ e(a + b × Predictor 1 + c × Predictor 2 + d × Predictor 3)
replacing a, b, c, d and the predictors by the coefficients and
respective variables listed in Table 3. Predictors included the
following variables in different combinations: age at baseline;
viral load at baseline; RTE percentage among CD4+ T cells at
6 months of ART; CD4+ T cell count slope from baseline to 6
months of ART; ratio of RTE percentages among CD4+ T cells
at baseline and 6 months of ART; CD4+ T cell counts at 2 and
6 months of ART. The best of these four models regarding the
goodness-of-fit (AUC = 0.91) and accuracy (87.1%), combined
age, plasma viral load at baseline and CD4+ T cell counts at
2 months of ART (Table 3, Model 4). To compare the relative
quality of the models using AIC, we used a fixed data set with
no missing values. Data of five patients had to be excluded, and
four models (Model 1′ to 4′), including the same variables of
Models 1–4, were built using data from the remaining 28 patients.
Considering the AIC, the best of these models combined age,
plasma viral load at baseline and CD4+ T cell counts at 6 months
of ART (Table S6, Model 3′).
For each of the Models 1–4, patients that failed to be correctly
identified (i.e., PIR identified as “Probably AIR” or AIR identified
as “Probably PIR”) presented values in the included variables that,
in combination, led to their inclusion in the opposite patient
group (Table S7). We found no single variable responsible for
the failure of the model in predicting patient’s immune recovery
outcome.
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FIGURE 4 | No major differences were observed in intrathymic proliferation
between AIR and PIR. (A) sj-TRECs/105 PBMCs, (B) sj-TRECs/mL of whole
blood and (C) sj/β TREC ratios were compared throughout ART between AIR
and PIR. A Wilcoxon-Mann-Whitney U-test was performed to compare the two
groups of patients at each time point, and the corresponding r is presented as
a measure of effect size. *Significant after Bonferroni correction (α/5 = 0.010).
DISCUSSION
Despite the extensive literature regarding PIR, there is currently
no consensus on their definition, hampering their identification
and clinical management and contributing to their poorer
prognoses compared to other HIV-infected patients. Here, we
aimed to distinguish and define PIR and AIR by clustering
analysis of the trajectories of CD4+ T cell counts during
therapy, and to build logistic models to predict PIR status using
parameters assessed during the first months of ART. Although
mathematical tools have been previously used to separate PIR and
AIR [e.g., Pérez-Santiago et al. used random forest classification
and unsupervised clustering to explore different definitions of a
discordant immune response (33)], to our knowledge, the use
of longitudinal cluster analysis has not been reported in this
context. Our results revealed that PIR presented lower HIV
viral load, CD4/CD8 ratio, naïve/memory CD4+ T cell ratio
and, most importantly, lower thymic function, strengthening
the importance of thymus in immune recovery during ART.
Furthermore, our logistic models were able to correctly predict
PIR/AIR outcome after 36 months of therapy in up to 87% of
cases, based on observations made until 2–6 months after ART
onset.
This study included only severely lymphopenic patients (<200
CD4+ T cells/µL), in order to limit the effect of variation in
counts at baseline, which itself can explain distinct patterns
of immune recovery (34). Limiting our sample to severely
lymphopenic patients is also of particular interest given that these
patients present a higher risk of new AIDS-defining events and
death (22, 35).
The importance of the thymus in HIV pathogenesis and in
immune recovery during ART is well-recognized. Several studies
have shown that both adults and children infected by HIV
present thymic alterations that may be reversed during ART;
and that higher estimates of thymic function in patients on
therapy are associated with higher CD4+ T cell counts and better
immune recoveries (36–38). Here we saw that AIR exhibited
higher levels of thymic function than PIR by the following
metrics: higher percentage of RTE among CD4+ T cells at 12,
24, and 36 months of ART; higher number of sj-TRECs and a
greater sj/β TREC ratio at 24 months of ART; and significant
increase in thymic volume between baseline and 12 months of
ART. The observation regarding RTE percentages suggests that
thymic function is superior in AIR before and during therapy,
and thymic volume gain in AIR, but not in PIR, points to a
higher functional regeneration potential/capacity. Interestingly,
our data also suggest that thymic function regeneration is more
evident in AIR in comparison to a group of HIV-infected
individuals initiating ART with CD4+ T cell counts ranging
between 200 and 350 cells/µL. The observed differences in
naïve/memory CD4+ T cell ratio and RTE percentage among
CD4+ T cells are particularly interesting as they may relate to the
mechanism behind the divergent trajectories of immune recovery
between PIR and AIR. They point to a scenario in which the two
groups present different dynamics within the naïve and memory
CD4+ T cell subpopulations, probably related to distinct thymic
functions. These results are in accordance with previous studies
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FIGURE 5 | AIR had higher percentages of RTE (CD31+CD45RA+) among CD4+ T cells since baseline. (A) RTE percentage among CD4+ T cells and (B) their
absolute numbers were compared throughout ART between AIR and PIR. A Wilcoxon-Mann-Whitney U-test was performed to compare the two groups of patients at
each time point, and the correspondent r is presented as a measure of effect size. *Significant after Bonferroni correction (α/5 = 0.010).
TABLE 3 | Statistical comparison of the multivariate logistic regression models.
Logistic regression
Models Coefficients Predictor variables LRTa p-valueb ROC analysis
AUC Accuracyc Sensitivity/ Specificity
Model 1
(n = 31)
a = −8.670
b = −0.102
c = 1.985
d = 0.105
Age at baseline
Log HIV plasma VL at baseline
% RTE among CD4+ T cells at 6 mo
p= 0.537 0.084
0.019
0.061
0.861 77.4% 76.5/78.6%
Model 2
(n = 30)
a = −15.182
b = 2.519
c = 0.133
d = −2.179
Log HIV plasma VL at baseline
CD4+ T cell count slope [0, 6] mo
% RTE among CD4+ T cells ratio (0/6mo)
p= 0.112 0.051
0.029
0.038
0.871 76.7% 81.3/71.4%
Model 3
(n = 33)
a = −9.703
b = −0.103
c = 1.897
d = 0.013
Age at baseline
Log HIV plasma VL at baseline
CD4+ T cell count at 6 mo
p= 0.885* 0.071
0.029
0.037
0.902 84.8% 89.5/78.6%
Model 4
(n = 31)
a = −10.971
b = −0.160
c = 2.610
d = 0.012
Age at baseline
Log HIV plasma VL at baseline
CD4+ T cell count at 2 mo
p= 0.333
†
0.038
0.018
0.017
0.908 87.1% 94.1/78.6%
Models are ordered by increasing sensitivity.
aLikelihood ratio test (LRT) was used to compare the goodness of fit of reduced model (three final variables) vs. full model (initial variables); a non-significant p-value means that the
reduced model is as good as the full model.
bp-Value for each of the three predictors of the reduced model.
cAccuracy corresponds to the percentage of patients PIR or AIR that were respectively classified as “probably PIR” or “probably AIR” among all patients.
*LRT was performed using only 31 of the 33 patients due to missing values in variables that were excluded during the stepwise selection.
†
LRT was performed using only 29 of the 31 patients due to missing values in variables that were excluded during stepwise selection.
AUC, area under the ROC curve; LRT, likelihood ratio test; mo, months; p, p-value; ROC, receiver operating characteristic curve; VL, viral load.
focusing on poor immunologic responses to ART, either with
case-control (39), cross-sectional (40) or longitudinal designs
(21, 41).
RTE were identified as CD31+CD45RA+CD4+ T cells, which
represent a subset of naïve CD4+ T cells with high TREC
content (42). Some limitations in the usage of CD31 have been
identified, such as: (1) TCR-induced activation down-regulates
CD31 expression (43, 44); (2) some CD4+CD45RA+CD31+ cells
undergo in vivo peripheral proliferation without immediate loss
of CD31, resulting in an accumulation of CD45RA+CD31+
proliferative offspring (45, 46); (3) thymectomised individuals
maintain a population of CD31+ T cells in circulation (47).
Notwithstanding these limitations, it is still one of the most well
established markers of RTE.
A decrease in thymic function is associated with aging (48–
50). Even though we found no significant age differences between
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PIR and AIR, PIR tended to be older, a tendency that might
explain the reduced thymic function presented by this group.
This possibility is particularly important given that age at baseline
was included in the predictive models discussed below. If age
alone could account for the differences in surrogates of thymic
function, we would expect an inverse correlation between age
and these parameters. Such correlations have been described by
others in the context of HIV infection or hematopoietic stem-
cell transplantation (16, 51, 52). However, we saw no correlations
between age and any surrogates of thymic activity in our cohort,
which might be related to the narrow age range of this cohort:
all but two AIR and one PIR were over age 30. It might also be
that improvement in thymic function during ART is, to a certain
extent, independent of patient age, at least for these patients’ age
range.
PIR presented significantly lower HIV plasma loads at
baseline, as reported in other studies (53–56). This association
may seem counterintuitive, given that higher plasma viral
loads have been associated with disease progression and poorer
prognosis (57–59). One possible explanation is that the high
HIV plasma loads in AIR are the main factor contributing
to the lymphopenia, so the suppression of HIV replication
by ART results in an adequate immunological response;
while in PIR, typically with low HIV plasma loads, different
mechanisms contribute to the lymphopenia and the effectiveness
of ART to counterbalance each of these mechanisms is
limited.
To build predictive models to identify PIR as early as possible,
we focused on parameters at baseline, 2 or 6 months of ART.
While the univariate logistic regressions showed that CD4+ T
cell counts at 2 or 6 months of ART, and the slope between
baseline and 6 months of ART were the single variables with
highest predictive value, the multivariate analyses allowed us
to build models with greater prediction accuracies. Of the
four multivariate models described here, the one including age
and plasma viral load at baseline, and RTE percentage among
CD4+ T cells at 6 months of ART (Model 1) performed better
than any of the univariate models, despite excluding CD4+
T cell counts. Furthermore, the model which included age
and plasma viral load at baseline, and CD4+ T cell count
at 2 months of ART (Model 4) was able to correctly predict
AIR/PIR status in 87.1% of the cases, with high sensitivity
and specificity (94.1 and 78.6%, respectively). Although these
results are encouraging, it should be highlighted that they were
obtained using a relatively small number of patients of a single
hospital. Therefore, replication of our analyses in other cohorts
or encompassing larger numbers of patients will be of great
value.
In contrast with our results, others have shown greater
numbers of Treg and higher levels of cell proliferation and
activation in PIR (30–32). These differences might be due to
the exclusive analysis of patients with CD4+ T cell counts
<200 cells/µL at ART onset in our study, or to distinct
criteria to define PIR and AIR. It has been shown that severely
lymphopenic patients present higher percentage of Treg, lower
percentage of Treg with a naïve phenotype and impaired
production of Treg by the thymus, a phenotype not observed
for patients starting ART with higher CD4+ T cell counts (>350
cells/µL) (60).
The major strengths of this study are the longitudinal
prospective design, with several evaluations over at least 36
months of therapy, and the multi-parametric evaluation of
thymic activity, since each method alone is indirect and presents
its own advantages and limitations [reviewed in (61)]. Our
results show that persistent differences in thymic function
in severely lymphopenic HIV-infected patients are associated
with distinct immune recoveries that diverge soon after ART
initiation. The outcome of PIR can be improved by early
identification of these patients. This will prompt closer follow-
up and possibly, in the future, the administration of strategies
to boost thymic function. As pre-clinical and clinical trials
aiming to enhance thymic function are currently on-going,
studies like the one presented here might help to select the
patients that could benefit the most from novel therapeutic
approaches.
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